Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 11, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Dec. 11, 2020 - Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA trial at the 2020 SABCS Read
- Dec. 9, 2020 - Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET trial at the 2020 SABCS Read
- Dec. 9, 2020 - Puma Biotechnology Presents Updated Results from the Phase II SUMMIT trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Read
- Dec. 2, 2020 - Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted Read
- Nov. 17, 2020 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) Read
- Nov. 6, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Nov. 5, 2020 - Puma Biotechnology Reports Third Quarter 2020 Financial Results Read
- Nov. 5, 2020 - Puma Biotechnology Announces Interim Results from the Phase II SUMMIT trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer Read
- Nov. 3, 2020 - Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference Read
- Oct. 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
- Oct. 15, 2020 - NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers Read
- Oct. 5, 2020 - Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer Read
- Oct. 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Sept. 8, 2020 - Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Read
- Sept. 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 19, 2020 - Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL trial in Annals of Oncology Read
- Aug. 10, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Aug. 6, 2020 - Puma Biotechnology Reports Second Quarter 2020 Financial Results Read
- July 27, 2020 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers Read
- July 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
- July 16, 2020 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage HER2-Positive Breast Cancer Read
- July 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- June 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- May 8, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- May 7, 2020 - Puma Biotechnology Reports First Quarter 2020 Financial Results Read
- May 7, 2020 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage HER2-Positive Breast Cancer Read
- May 6, 2020 - Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020 Read
- April 30, 2020 - Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea Read
- April 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
- April 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- March 25, 2020 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
- March 5, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Feb. 28, 2020 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference Read
- Feb. 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to treat HER2-Positive Metastatic Breast Cancer Read
- Feb. 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
- Feb. 7, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Feb. 5, 2020 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results Read
- Jan. 13, 2020 - Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference Read
- Jan. 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
- Jan. 7, 2020 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Read